Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease
Our mission
AAVantgarde's mission is to retain and rejuvenate sight for patients with inherited retinal disorders (IRDs) by next-generation therapies.
Discover how our technology works
Watch the video to learn how our innovation can address the root cause of IRDs derived from large gene mutations
Delivering the next generation of therapies for IRDs caused by large genes
Focused on addressing the root cause of Stargardts disease and Usher 1B
Advancing our platforms
Our pipeline addresses IRDs with high unmet need and we have the potential to expand to other therapeutic areas with our technology
Delivering large genes like ABCA4 has been a challenge in the field. Our approach, validated by rigorous preclinical studies showing quantified high transduction, expression and long-term safety in multiple relevant models, offers a potential therapeutic that addresses the genetic root cause for patients with Stargardts disease.